Nagoya Protocol: ‘a masterpiece of ambiguity’

Since the Nagoya Protocol was implemented in October 2014, lawyers, academics, and the life sciences industry broadly have been calling upon institutions such as the European Union for guidance on how to best abide by the new regulations.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

In-house counsel

WATCH: LEO Pharma head of IP rights on doing more with less

7 October 2026 With resources under pressure, the Danish company’s IP leader explains how AI, smarter prioritisation and close business ties can help IP teams boost their impact.

Pharma

Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom

6 October 2026 Day one of the UK patent trial over blockbuster drug Jardiance put a lack of biological data, disputed evidence of testing and the limits of scientific prediction under the spotlight.

Careers

Latham adds ‘exceptional’ ITC expert and 5th trial lawyer in a year

6 October 2026 The new partner advises technology and life sciences companies in Section 337 investigations and related patent disputes, drawing on extensive private practice and government experience.

More features

WATCH: LEO Pharma head of IP rights on doing more with less

Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom

Latham adds ‘exceptional’ ITC expert and 5th trial lawyer in a year

Roche, Marques counsel: The fight against ‘deadly’ counterfeits is a race for the newest and best tech

Fish & Richardson nets patent litigator to grow European practice

What's AI best at? In-house teams are still learning

WATCH: Genevant IP director on tackling UPC-EPO opposition divide

5 LSPN takeaways: What’s keeping Europe’s IP teams on their toes?

Nagoya Protocol: ‘a masterpiece of ambiguity’

More on this story

Editor's picks

Editor's picks

More features